B-cell Acute Lymphoblastic Leukemia Clinical Trials in Chicago, Illinois

3 studies are recruiting for b-cell acute lymphoblastic leukemia in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

    This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

    Stage
    Phase 2
    Ages
    7 to 25
    Site
    Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
    Locations
    16 in total
    Run by
    Etan Orgel

    See if you can join NCT05082519 on ClinicalTrials.gov

  2. ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

    This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Chicago Comprehensive Cancer Center, Chicago, Illinois
    Locations
    4 in total
    Run by
    Marlise Luskin, MD

    See if you can join NCT03595917 on ClinicalTrials.gov

  3. Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

    This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the…

    Stage
    Phase 1
    Ages
    15 to 50
    Site
    University of Chicago, Chicago, Illinois
    Locations
    19 in total
    Run by
    Cellectis S.A.

    See if you can join NCT04150497 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.